Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2020 3
2021 2
Text availability
Article attribute
Article type
Publication date

Search Results

6 results
Results by year
Filters applied: . Clear all
Page 1
Effectiveness and safety of vedolizumab in inflammatory bowel disease patients aged 60 and over: an observational multicenter UK experience.
Ibraheim H, Samaan MA, Srinivasan A, Brain O, Digby-Bell J, Irving PM, Norman I, Jawad I, Biedermann J, Ibarra A, Kok KB, Parkes G, Rimmer J, Compot E, Parkes M, Segal J, Oppong P, Hart A, Hayee B, Powell N. Ibraheim H, et al. Among authors: kok kb. Ann Gastroenterol. 2020 Mar-Apr;33(2):170-177. doi: 10.20524/aog.2020.0447. Epub 2020 Jan 7. Ann Gastroenterol. 2020. PMID: 32127738 Free PMC article.
IBD in pregnancy: recent advances, practical management.
Selinger CP, Nelson-Piercy C, Fraser A, Hall V, Limdi J, Smith L, Smith M, Nasur R, Gunn M, King A, Mohan A, Mulgabal K, Kent A, Kok KB, Glanville T. Selinger CP, et al. Among authors: kok kb. Frontline Gastroenterol. 2020 May 19;12(3):214-224. doi: 10.1136/flgastro-2019-101371. eCollection 2021. Frontline Gastroenterol. 2020. PMID: 33912333 Free article. Review.
Standards for the provision of antenatal care for patients with inflammatory bowel disease: guidance endorsed by the British Society of Gastroenterology and the British Maternal and Fetal Medicine Society.
Selinger C, Carey N, Cassere S, Nelson-Piercy C, Fraser A, Hall V, Harding K, Limdi J, Smith L, Smith M, Gunn MC, Mohan A, Mulgabal K, Kent A, Kok KB, Glanville T. Selinger C, et al. Among authors: kok kb. Frontline Gastroenterol. 2020 May 7;12(3):182-187. doi: 10.1136/flgastro-2020-101459. eCollection 2021. Frontline Gastroenterol. 2020. PMID: 33912332 Free PMC article.
Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
Biancheri P, Brezski RJ, Di Sabatino A, Greenplate AR, Soring KL, Corazza GR, Kok KB, Rovedatti L, Vossenkämper A, Ahmad N, Snoek SA, Vermeire S, Rutgeerts P, Jordan RE, MacDonald TT. Biancheri P, et al. Among authors: kok kb. Gastroenterology. 2015 Nov;149(6):1564-1574.e3. doi: 10.1053/j.gastro.2015.07.002. Epub 2015 Jul 11. Gastroenterology. 2015. PMID: 26170138 Free article.
Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab.
Kennedy NA, Goodhand JR, Bewshea C, Nice R, Chee D, Lin S, Chanchlani N, Butterworth J, Cooney R, Croft NM, Hart AL, Irving PM, Kok KB, Lamb CA, Limdi JK, Macdonald J, McGovern DP, Mehta SJ, Murray CD, Patel KV, Pollok RC, Raine T, Russell RK, Selinger CP, Smith PJ, Bowden J, McDonald TJ, Lees CW, Sebastian S, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Kennedy NA, et al. Among authors: kok kb. Gut. 2021 May;70(5):865-875. doi: 10.1136/gutjnl-2021-324388. Epub 2021 Mar 22. Gut. 2021. PMID: 33753421 Free PMC article.
Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD.
Kennedy NA, Lin S, Goodhand JR, Chanchlani N, Hamilton B, Bewshea C, Nice R, Chee D, Cummings JF, Fraser A, Irving PM, Kamperidis N, Kok KB, Lamb CA, Macdonald J, Mehta S, Pollok RC, Raine T, Smith PJ, Verma AM, Jochum S, McDonald TJ, Sebastian S, Lees CW, Powell N, Ahmad T; Contributors to the CLARITY IBD study. Kennedy NA, et al. Among authors: kok kb. Gut. 2021 Apr 26:gutjnl-2021-324789. doi: 10.1136/gutjnl-2021-324789. Online ahead of print. Gut. 2021. PMID: 33903149 Free PMC article.